Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Ketosphinganine synthase inhibitor
ALX-106-037-M100 100 mg 169.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: BML-SL200

Excitatory amino acid. Inhibitor of ketosphinganine synthase (serine-palmitoyl-CoA transferase, EC, leading to blockade of sphingosine biosynthesis. Partial agonist at the glycine modulatory site of the NMDA receptor.

Product Specification

Alternative Name:S(-)-4-Amino-3-isoxazolidinone
MI:14: 2751
Purity:≥98% (HPLC)
Appearance:White to off-white powder.
Solubility:Soluble in water.
Long Term Storage:-20°C
Use/Stability:Unstable in neutral or acidic solutions.
Please mouse over

Product Literature References

D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain: I.P. Chessell, et al.; Brain Res. 565, 345 (1991), Abstract;
Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor: G.S. Shukla, et al.; Biochim. Biophys. Acta 1083, 101 (1991), Abstract;
D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes: G.B. Watson, et al.; Brain Res. 510, 158 (1990), Abstract;
Inhibition of serine palmitoyltransferase activity in rabbit aorta by L-cycloserine: R.D. Williams, et al.; J. Lipid Res. 28, 1478 (1987), Abstract; Full Text
Inhibition of sphingolipid synthesis by cycloserine in vitro and in vivo: K.S. Sundaram & M. Lev; J. Neurochem. 42, 577 (1984), Abstract;

Related Literature

Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

Technical Posters
Arachidonic Acid Metabolites
Arachidonic Acid Metabolites
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,